OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ruan Discusses BTK Inhibitors in MCL

February 22nd 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Levy Discusses the FLAURA Study in Lung Cancer

February 22nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

Dr. Denham on Hyperprogression in Patients With NSCLC

February 21st 2018

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

February 21st 2018

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

February 20th 2018

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Overman on Remaining Questions With Immunotherapy in CRC

February 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Autologous Stem Cell Transplantation in Multiple Myeloma

February 20th 2018

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Dr. Pishvaian on the Future of Entrectinib in Pancreatic Cancer

February 20th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of entrectinib in the treatment of patients with pancreatic cancer.

Dr. Barrientos Discusses Combination Strategies in CLL

February 20th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of recent combination trials for patients with chronic lymphocytic leukemia (CLL).

Dr. Sullivan on Targeted Therapy for BRAF-Mutant Melanoma

February 20th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses novel molecular targets in patients with melanoma.

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

February 20th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

February 20th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL

February 20th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

February 19th 2018

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

Dr. Schwartz on the Results of the PACIFIC Trial

February 19th 2018

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).

Dr. Shiller on the Challenges in the Development of NSCLC Biomarkers

February 17th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the difficulties that are preventing a more streamlined approached in testing for biomarkers.

Dr. Mason on the Intersection of Surgery and Biomarkers in NSCLC

February 17th 2018

David P. Mason, MD, Baylor Scott & White Center for Thoracic Surgery, discusses a case that demonstrates the evolution of lung cancer surgery in a biomarker-driven era.